Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Arslan, Burak; Arslan, Gökçe Ayhan; Tuncer, Aslı; Karabudak, Rana; Dinçel, Aylin Sepici

doi:10.17305/bjbms.2021.7326

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a useful marker for disease monitoring in amyotrophic lateral sclerosis [6], multiple sclerosis [7], Alzheimer's disease [8,9], and more recently Huntington's disease [10]. It is also promising marker for follow-up of patients with brain tumors [11]. Higher levels of blood or CSF NF-L have been associated with increased mortality, as would be expected as release of this protein reflects ongoing axonal loss [12].…”

Section: Nf-l As Diagnostic Toolmentioning

confidence: 99%

Multiple sclerosis: progress in detection and therapy?

2023

MCR

View full text Add to dashboard Cite

Diagnosis and therapy of multiple sclerosis (MS) are not optimal so far, they need improvement. We present a diagnostic parameter and two therapeutic methods that offer a prospect of success without burdening the patient. They are the biomarker Nf-L for the evaluation of the status of the lesions of the neural axons and the application of two treatment methods of endogenous origin: PEA (N-Palmitoylethanolamin) and intracellular Enzymes. They are suitable for MS in terms of their effects. The good experience gained so far suggests that it would be worthwhile to test them in detailed studies.

show abstract

Section: Nf-l As Diagnostic Toolmentioning

confidence: 99%

Multiple sclerosis: progress in detection and therapy?

2023

MCR

View full text Add to dashboard Cite

show abstract

“…Corrigendum to: Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective [ 1 ].…”

mentioning

confidence: 99%

Corrigendum: Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Editors¹

2023

Biomol Biomed

View full text Add to dashboard Cite

Corrigendum to: Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective. This corrigendum corrects funding information to: This project was partly supported by Gazi University Scientific Research Projects Coordination Unit (BAP) (project code: 01/2019-38). The authors would like to thank Gazi University for funding this project. The authors sincerely apologize for the error and confirm that this correction does not change the conclusion of the article.

show abstract

Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis

Passali,

Galea,

Knudsen

et al. 2024

J Neurol

View full text Add to dashboard Cite

Background Studies on the capability of cerebrospinal fluid neurofilament light chain (cNfL) to predict multiple sclerosis (MS) conversion in clinically isolated syndromes have yielded varying results. Objectives To expand our understanding of cNfL in optic neuritis (ON) and investigate whether incorporating cNfL into the 2017 McDonald criteria could accelerate the diagnosis of MS in patients with ON. Methods cNfL was measured in diagnostic samples from 74 patients with verified ON. MS was diagnosed using the 2017 McDonald criteria with a minimum observation time of two years from ON onset. Results 20.5% of 44 MS-converters did not fulfil the 2017 McDonald criteria at ON onset. A doubling of cNfL was associated with 207% (74%–514%) higher odds of MS (p = 0.00042, adjusted for age). Fulfilment of ≥ 1 MRI criterion for dissemination in space (DIS) and presence of brain contrast-enhancing lesions were associated with higher cNfL. Furthermore, cNfL correlated with inter-eye differences in retinal nerve fiber layer (RNFL) thickness (Spearman’s ρ = 0.46, p = 8 × 10–5). Incorporating cNfL ≥ 906 pg/mL as a substitute for either dissemination in time or one MRI criterion for DIS increased the sensitivity (90.9% vs. 79.6%) and accuracy (91.9% vs. 87.8%), but also reduced the specificity (93.3% vs. 100%) of the 2017 McDonald criteria. Conclusion cNfL was related to MS diagnostic parameters and the degree of RNFL swelling. Clinical use of cNfL may aid in identification of ON patients with increased risk of MS until larger studies have elaborated on the potential loss of specificity if used diagnostically.

show abstract

Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Cited by 3 publications

References 32 publications

Multiple sclerosis: progress in detection and therapy?

Multiple sclerosis: progress in detection and therapy?

Corrigendum: Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective

Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis

Contact Info

Product

Resources

About